Despite its importance, ERBB2 testing poses several challenges. Variability in IHC scoring and interpretation can lead to inconsistent results. The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) have established guidelines to standardize testing procedures, but discrepancies can still occur. Additionally, some tumors exhibit heterogeneity in ERBB2 expression, complicating the assessment.
